‘Text/HTML’ of page ‘NRG-CC004’
Comparing Two Dose Levels of Bupropion Versus Placebo for Sexual Desire DOWNLOAD OR PRINT THE PDF OF THIS STUDY RESULTS SUMMARY
Read MoreContent Block Tag: NRG-CC004
‘Text/HTML’ of page ‘NRG-CC004’
Summary of Research Results for NRG-CC004
Read More‘NRG-CC004 Documentation’ of page ‘NRG-CC004’
Protocol Documents NRG-CC004 Protocol NRG-CC004 Consent Memos and Letters Initial Study Activation Memo IND Exemption Letter Forms Study Agent Shipment Form (SASF) Drug Destruction Form NRG-CC004 Blank Forms NRG-CC004 Eligibility Checklist form Step 1 NRG-CC004 Eligibility Checklist form Step 2 NRG- CC004 Data Submission Forms for Participants (requires IRB approval) NRG-CC004 Participant Instruction sheet – Blinded […]
Read More‘NRG-CC004’ of page ‘NRG-CC004’
Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo For Sexual Desire in Women With Breast or Gynecologic Cancer Principal Investigator Deb Barton, PhD, RN Primary Objective Measure the ability of two dose levels of bupropion, 150 or 300 mg of extended release, to improve sexual desire more than a placebo at 9 […]
Read More